---
title: CDMO Daily News — September 1, 2026
slug: daily-news-2026-09-01-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 1 CDMO daily: Evonik Invests $108M in Vancouver Lipid-Drug Manufacturing Facility; Ennolys Expands CDMO Services in Fermentation, DSP, and Drying —…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-01-cdmo
published_at: 2026-09-01T00:00:14.252Z
last_updated: 2026-09-01T00:02:24.112Z
---

### [Evonik](/companies/evonik) Invests $108M in Vancouver Lipid-Drug Manufacturing Facility
- [Evonik](/companies/evonik) is building a new GMP drug-product facility in Vancouver with CAD 150M ($108M) investment, supported by CAD 68M ($49M) in Canadian federal funding.
- The facility will deliver 3× current capacity for lipid-based drug delivery and launch commercial production by end of 2029.
- Expanded quality control and microbiological testing capabilities will support clinical and commercial-scale development for pharma and biotech customers.

**Operational Impact**

[Evonik](/companies/evonik)'s Vancouver facility adds significant APAC-adjacent lipid-drug-product capacity by 2029, reducing regional bottlenecks for biotech sponsors scaling lipid-based programs toward commercial launch.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/evonik-invests-108m-in-new-lipid-based-drug-manufacturing-facility-in-canada)*

---

### [Ennolys](/companies/ennolys) Expands CDMO Services in Fermentation, DSP, and Drying
- [Ennolys](/companies/ennolys) is expanding CDMO capabilities to cover fermentation, downstream processing (DSP), and drying for biotech projects from R&D through commercial production.
- The service leverages 30+ years of fermentation expertise and large-capacity fermenters to optimize yields, quality, and reproducibility for enzymes, probiotics, proteins, and peptides.
- Expansion aims to help manufacturers reduce development costs, accelerate time to market, and secure supply chains across food, cosmetics, nutraceuticals, and animal nutrition markets.

**Operational Impact**

[Ennolys](/companies/ennolys)'s expanded fermentation and DSP capabilities add CDMO capacity for biotech manufacturers seeking integrated development-to-production support, particularly for fermentation-derived biologics and metabolites in food, cosmetics, and nutraceutical markets.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/ennolys-expands-cdmo-services-across-fermentation-and-bioprocessing)*

## References

1. [PharmaSource RSS — Evonik Invests $108M in Vancouver Lipid-Drug Manufacturing Facility](https://pharmasource.global/content/news/cdmo-news/evonik-invests-108m-in-new-lipid-based-drug-manufacturing-facility-in-canada)
2. [PharmaSource RSS — Ennolys Expands CDMO Services in Fermentation, DSP, and Drying](https://pharmasource.global/content/news/cdmo-news/ennolys-expands-cdmo-services-across-fermentation-and-bioprocessing)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-01-cdmo